Outcomes of primary refractory multiple myeloma and the impact of novel therapies

E-ISSN： 1096-8652|90|11|981-985

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : 981-985

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents

By Madan Sumit Kumar Shaji

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 415-429

Future Medicine

Access to resources Recommend Favorite

Primary Hyperparathyroidism in an Elderly Patient with Multiple Myeloma

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 40, Iss. 7, 1992-07 ,pp. : 703-705

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3622-3630

John Wiley & Sons Inc

Access to resources Recommend Favorite